DAVENPORT & Co LLC raised its position in Natera, Inc. (NASDAQ:NTRA – Get Rating) by 23.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,599 shares of the medical research company’s stock after purchasing an additional 673 shares during the quarter. DAVENPORT & Co LLC’s holdings in Natera were worth $336,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Fifth Third Bancorp boosted its holdings in Natera by 6.3% in the 4th quarter. Fifth Third Bancorp now owns 5,285 shares of the medical research company’s stock valued at $494,000 after purchasing an additional 313 shares during the last quarter. Brown Advisory Inc. boosted its holdings in Natera by 395.5% in the 4th quarter. Brown Advisory Inc. now owns 343,543 shares of the medical research company’s stock valued at $32,084,000 after purchasing an additional 274,205 shares during the last quarter. Banque Pictet & Cie SA boosted its holdings in Natera by 530.6% in the 4th quarter. Banque Pictet & Cie SA now owns 122,081 shares of the medical research company’s stock valued at $11,401,000 after purchasing an additional 102,720 shares during the last quarter. Foundry Partners LLC boosted its holdings in Natera by 8.7% in the 4th quarter. Foundry Partners LLC now owns 3,420 shares of the medical research company’s stock valued at $319,000 after purchasing an additional 275 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in Natera by 29.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 37,660 shares of the medical research company’s stock valued at $3,517,000 after purchasing an additional 8,650 shares during the last quarter. Institutional investors own 96.24% of the company’s stock.
In other news, insider Daniel Rabinowitz sold 884 shares of the company’s stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $42.16, for a total value of $37,269.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 894 shares of the company’s stock in a transaction on Friday, April 22nd. The shares were sold at an average price of $36.14, for a total transaction of $32,309.16. Following the completion of the transaction, the chief executive officer now owns 63,122 shares of the company’s stock, valued at approximately $2,281,229.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,332 shares of company stock worth $659,678. Insiders own 10.86% of the company’s stock.
Natera (NASDAQ:NTRA – Get Rating) last announced its quarterly earnings data on Friday, May 6th. The medical research company reported ($1.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.05. Natera had a negative net margin of 81.90% and a negative return on equity of 95.80%. The company had revenue of $194.13 million for the quarter, compared to the consensus estimate of $176.61 million. During the same period in the prior year, the firm posted ($0.74) EPS. The company’s quarterly revenue was up 27.5% compared to the same quarter last year. Analysts forecast that Natera, Inc. will post -6.05 EPS for the current year.
NTRA has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Wednesday. StockNews.com raised shares of Natera to a “sell” rating in a research note on Monday. Stephens started coverage on shares of Natera in a research note on Monday, April 25th. They issued an “overweight” rating and a $54.00 price target on the stock. Morgan Stanley reduced their price target on shares of Natera from $118.00 to $110.00 and set an “overweight” rating on the stock in a research note on Monday, February 28th. Finally, BTIG Research reduced their price target on shares of Natera from $125.00 to $100.00 in a research note on Thursday, March 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Buy” and an average price target of $100.50.
Natera Company Profile (Get Rating)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
- Get a free copy of the StockNews.com research report on Natera (NTRA)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.